Related Experiment Videos
Recent advances in the management of renal osteodystrophy in children
I B Salusky1, J A Ramirez, W G Goodman
1University of California at Los Angeles School of Medicine.
Insights
Secondary hyperparathyroidism is common in pediatric dialysis patients. New management strategies like avoiding aluminum and using calcitriol therapy show promise for effective treatment in end-stage renal disease.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Mineral and Bone Disorders
Background:
- Secondary hyperparathyroidism is a primary histologic finding in pediatric dialysis patients.
- Calcium regulation of parathyroid hormone secretion is similar in patients with osteitis fibrosa and healthy individuals.
- Growth retardation and skeletal deformities are key features of renal osteodystrophy in children.
Purpose of the Study:
- To review the management of secondary hyperparathyroidism in pediatric end-stage renal disease.
- To highlight the roles of vitamin D and insulin-like growth factor in pediatric renal osteodystrophy.
- To discuss newer therapeutic approaches for secondary hyperparathyroidism.
Main Methods:
- Literature review of recent evidence on secondary hyperparathyroidism in pediatric dialysis patients.
- Analysis of factors contributing to growth retardation and skeletal deformities.
- Evaluation of novel management strategies including calcitriol therapy and aluminum avoidance.
Main Results:
- Parathyroid hormone secretion regulation by calcium is comparable between affected children and healthy subjects.
- Vitamin D metabolism and insulin-like growth factor alterations contribute to skeletal issues.
- Effective management strategies are emerging for pediatric secondary hyperparathyroidism.
Conclusions:
- Secondary hyperparathyroidism management in pediatric end-stage renal disease requires a multifaceted approach.
- Aluminum avoidance and intermittent calcitriol therapy represent significant advancements.
- Addressing growth and skeletal issues is crucial for improving patient outcomes.
Abstract:
Secondary hyperparathyroidism remains the predominant histologic lesion in pediatric patients undergoing regular dialysis, but recent evidence indicates that the regulation of parathyroid hormone secretion by calcium does not differ substantially between patients with osteitis fibrosa and subjects with normal renal function. Growth retardation and skeletal deformities are major findings in pediatric patients with renal osteodystrophy, and alterations in vitamin D metabolism and insulin-like growth factor almost certainly contribute to these findings. Avoidance of aluminum-containing medications and the introduction of intermittent calcitriol therapy provide newer approaches to the effective management of secondary hyperparathyroidism in pediatric patients with end-stage renal disease.